Schonfeld Group Holdings’s Achillion Pharmaceuticals ACHN Stock Holding History

Schonfeld Group Holdings’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$136K	Buy	+12,578	New	+$114K	0.09%	230

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schonfeld Group Holdings's ACHN Position: Q4 2015 in Review

Schonfeld Group Holdings opened a new position in Achillion Pharmaceuticals (ACHN) in Q4 2015: 12,578 shares worth $136K. The stake represents 0.09% of the portfolio and ranks #230 among its holdings.

152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

Schonfeld Group Holdings held 12,578 shares of Achillion Pharmaceuticals worth $136K as of Q4 2015.
Achillion Pharmaceuticals was a new Schonfeld Group Holdings position in Q4 2015.
Achillion Pharmaceuticals made up 0.09% of Schonfeld Group Holdings's portfolio in Q4 2015, its #230 holding.
152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on Schonfeld Group Holdings's 13F filing for Q4 2015, filed 12 Feb 2016.